With the knockdown of the upstream inhibitory target DNMT1, the highly expressed MEG3 shows high potential for cancer inhibition, including inhibiting cancer cell proliferation and promoting apoptosis, and inhibiting EMT through Notch1 signaling pathway. Here, NOTCH1 is linked to cancer.